Evidence map›Paper›PMID 42649932›Full record

ArticleCancers2026

Decitabine Reprograms Temozolomide-Resistant Glioblastoma Through Epigenetic Reactivation and Mesenchymal Attenuation: A Multi-Omics Study.

Itika Arora, Shamsa Hilal Saleh, Arshiya Akbar, Fareeha Arshad, Volodymyr Mavrych, Olena Bolgova, Faisal Abdulhameed Farrash, Ahmed Abu-Zaid, Andleeb Khan, Sheikh Muskan and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Itika AroraCollege of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.
Shamsa Hilal SalehCollege of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.
Arshiya AkbarCollege of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.
Fareeha ArshadCollege of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.
Volodymyr MavrychCollege of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.ORCID 0009-0009-1159-4573
Olena BolgovaCollege of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.ORCID 0009-0002-9496-9754
Faisal Abdulhameed FarrashKing Faisal Specialist Hospital and Research Centre (KFSHRC), Riyadh 12713, Saudi Arabia.ORCID 0000-0003-3521-217X
Ahmed Abu-ZaidCollege of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.
Andleeb KhanDepartment of Biosciences, Faculty of Science, Integral University, Lucknow 226026, India.ORCID 0000-0001-6125-3309
Sheikh MuskanDepartment of Biosciences, Faculty of Science, Integral University, Lucknow 226026, India.
Mohammed Imran KhanKing Faisal Specialist Hospital and Research Centre (KFSHRC), Jeddah 23433, Saudi Arabia.
Ahmed YaqinuddinCollege of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.ORCID 0000-0001-7536-910X

Funding

Alfaisal University IRG# 25345
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

decitabineepigenetic de-repressionINPP5D/SHIP1interferon responsemesenchymal transitionmulti-omics integrationpharmacogenomicsPI3K–AKT signalingsingle-cell transcriptomicsTCGA-GBM survivaltemozolomide resistance

Identifiers

PMID42649932
PMCPMC13511076

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.